Literature DB >> 8059597

Bundles of amyloid precursor protein-immunoreactive axons in human cerebrovascular white matter lesions.

T Suenaga1, K Ohnishi, M Nishimura, S Nakamura, I Akiguchi, J Kimura.   

Abstract

Cerebral white matter lesions commonly observed in Binswanger's disease, multi-infarct encephalopathy and elderly people are neuropathologically characterized by diffuse incomplete demyelination and considered to be ischemic in nature. Arteriolosclerosis in the white matter is a common feature in these white matter lesions. To investigate a possible alteration of the distribution of amyloid precursor protein (APP), chromogranin A (CgA) and synaptophysin (Syn) in such white matter lesions, we examined 15 cases with white matter lesions and 5 without white matter lesions. Many bundles of axons with APP-like immunoreactivity (LI) were observed particularly in mild white matter lesions. Such bundles of axons showed similar but less intense CgA-LI and Syn-LI. They appeared to occur in areas with many ameboid or ramified microglia labeled with anti-leukocyte common antigen and few astrocytes labeled with anti-glial fibrillary acidic protein. In the center of moderate of severe white matter lesions bundles of axons with APP-LI were never observed. Since APP, CgA and Syn undergo fast axonal transport, and since following ischemic insults to central nervous system microglial reaction occurs earlier than astroglial changes, our results suggest that axonal damage, which induces disturbance of fast axonal transport, can occur even in the early stage of white matter lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8059597     DOI: 10.1007/bf00294171

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  40 in total

1.  Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized.

Authors:  P J Morin; C R Abraham; A Amaratunga; R J Johnson; G Huber; J H Sandell; R E Fine
Journal:  J Neurochem       Date:  1993-08       Impact factor: 5.372

2.  Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.

Authors:  N Kitaguchi; Y Takahashi; Y Tokushima; S Shiojiri; H Ito
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

3.  Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease.

Authors:  E Cochran; B Bacci; Y Chen; A Patton; P Gambetti; L Autilio-Gambetti
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

4.  Immunohistochemical investigation of cerebral ischemia after middle cerebral artery occlusion in gerbils.

Authors:  K Yamamoto; F Akai; T Yoshimine; T Yanagihara
Journal:  J Neurosurg       Date:  1987-09       Impact factor: 5.115

5.  Beta-amyloid precursor protein gene is differentially expressed in axotomized sensory and motor systems.

Authors:  J N Scott; I M Parhad; A W Clark
Journal:  Brain Res Mol Brain Res       Date:  1991-07

6.  Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischemia in the rat.

Authors:  D T Stephenson; K Rash; J A Clemens
Journal:  Brain Res       Date:  1992-10-09       Impact factor: 3.252

7.  Cumulative white matter changes in the gerbil brain under chronic cerebral hypoperfusion.

Authors:  H Hattori; M Takeda; T Kudo; T Nishimura; S Hashimoto
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Diffuse white-matter disease in the geriatric population. A clinical, neuropathological, and CT study.

Authors:  K Goto; N Ishii; H Fukasawa
Journal:  Radiology       Date:  1981-12       Impact factor: 11.105

9.  Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury.

Authors:  S M Gentleman; M J Nash; C J Sweeting; D I Graham; G W Roberts
Journal:  Neurosci Lett       Date:  1993-10-01       Impact factor: 3.046

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  6 in total

1.  Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age.

Authors:  Alfredo Ramos-Miguel; Andrea A Jones; Ken Sawada; Alasdair M Barr; Thomas A Bayer; Peter Falkai; Sue E Leurgans; Julie A Schneider; David A Bennett; William G Honer
Journal:  Neurobiol Dis       Date:  2018-02-26       Impact factor: 5.996

2.  rnaset2 mutant zebrafish model familial cystic leukoencephalopathy and reveal a role for RNase T2 in degrading ribosomal RNA.

Authors:  Noémie Haud; Firat Kara; Simone Diekmann; Marco Henneke; Jason R Willer; Melissa S Hillwig; Ronald G Gregg; Gustavo C Macintosh; Jutta Gärtner; A Alia; Adam F L Hurlstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-03       Impact factor: 11.205

3.  Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Authors:  Per Selnes; Kaj Blennow; Henrik Zetterberg; Ramune Grambaite; Lars Rosengren; Lisbeth Johnsen; Vidar Stenset; Tormod Fladby
Journal:  Cerebrospinal Fluid Res       Date:  2010-07-30

4.  White matter hyperintensity microstructure in amyloid dysmetabolism.

Authors:  Lisa F Kalheim; Atle Bjørnerud; Tormod Fladby; Kjetil Vegge; Per Selnes
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-20       Impact factor: 6.200

5.  Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model.

Authors:  Hideaki Wakita; Christl Ruetzler; Kachikwu O Illoh; Yong Chen; Asako Takanohashi; Maria Spatz; John M Hallenbeck
Journal:  J Cereb Blood Flow Metab       Date:  2007-07-18       Impact factor: 6.200

6.  Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions.

Authors:  H Tomimoto; I Akiguchi; T Suenaga; H Wakita; S Nakamura; J Kimura; H Budka
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.